Radioimmunotherapy

Subscribe to Selected New Research on Radioimmunotherapy

1329 relevant articles (196 outcomes, 217 trials/studies) found for this Therapy

Description: Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).

Also Known As:

Immunoradiotherapy; Immunoradiotherapies; Radioimmunotherapies

Relationship Network

Therapy Context: Research Results

Therapeutics: 6127

Combined Modality Therapy: 1614

Radioimmunotherapy: 1329

Biological Therapy: 935

Immunotherapy: 17822

Radioimmunotherapy: 1329

Radiotherapy: 196

Radioimmunotherapy: 1329

Experts

1.	Goldenberg, David M: 20 articles (07/2008 - 01/2002)
2.	Press, Oliver W: 16 articles (05/2008 - 05/2002)
3.	Witzig, Thomas E: 15 articles (09/2007 - 02/2002)
4.	Boerman, Otto C: 13 articles (06/2008 - 03/2003)
5.	Oyen, Wim J G: 13 articles (06/2008 - 03/2003)
6.	DeNardo, Gerald L: 11 articles (12/2005 - 01/2002)
7.	White, Christine A: 11 articles (12/2004 - 02/2002)
8.	Sharkey, Robert M: 10 articles (07/2008 - 05/2002)
9.	Emmanouilides, Christos: 10 articles (11/2007 - 02/2002)
10.	Pagel, John M: 9 articles (02/2008 - 03/2003)

Related Diseases

1.	Neoplasms (Cancer) 04/01/1999 - "However, as observed in other tumor types, the intratumoral distribution of the antibody is highly heterogeneous, which may limit the efficacy of radioimmunotherapy. " 12/15/1997 - "BACKGROUND: Nude mice with xenografted human tumors is the most exploited animal model used to elucidate the efficacy of experimental radioimmunolocalization and radioimmunotherapy. " 01/01/2008 - "Using a 2-step, pretargeting method that separates the bivalent anti-CEA antibody targeting of tumor from the delivery of the radioactive peptide that is captured by the second Fab of the tri-Fab construct, an improved method of cancer imaging and therapy has been developed and shows very sensitive and specific targeting of CEA-expressing tumors for either diagnostic imaging, such as with immunoSPECT and immunoPET, or radioimmunotherapy. " 07/01/1993 - "The proliferative rates of tumor cells may modify dose-rate effects further, and the interaction of all of these factors may explain in part the increased efficacy of low-dose-rate irradiation and radioimmunotherapy compared with high-dose-rate irradiation that has been reported in some animal models." 11/01/1986 - "The biologic half-life of the MAb mixture in the tumor was significantly greater than that of either MAb alone, suggesting the use of the MAb mixture in radioimmunotherapy." Order ALL the reference details at left...
2.	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/01/2006 - "Radioimmunotherapy has proven clinically effective in patients with non-Hodgkin's lymphoma. " 05/01/2004 - "Radioimmunotherapy produces overall response rates of approximately 80% in patients with low-grade lymphomas, and 25% to 30% of patients achieve a complete remission. " 06/01/2004 - "Radioimmunotherapy (RIT) using (131)I-tositumomab has been used successfully to treat relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). " 11/01/2008 - "Radioimmunotherapy is an effective treatment for non-Hodgkin's lymphoma (NHL). " 07/01/2008 - "Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody." Order ALL the reference details at left...
3.	Lymphoma (Lymphomas) 06/01/2001 - "Despite low radiation dose rates, radioimmunotherapy (RIT) has proven particularly effective in the treatment of malignancies, such as lymphoma. " 09/01/2003 - "Beta-irradiation used for systemic radioimmunotherapy (RIT) is a promising treatment approach for high-risk leukaemia and lymphoma. " 01/01/2009 - "EL4 lymphoma-bearing mice either were cured at higher doses of radioimmunotherapy alone or lower doses of radioimmunotherapy in synergy with chemotherapy. " 10/01/1999 - "Although more patients need to be evaluated with a longer follow-up period, radioimmunotherapy appears to be an effective and well-tolerated addition to the oncologists' armamentarium for relapsed lymphomas." 02/15/2004 - "Radioimmunotherapy (RIT) has emerged as an effective treatment for lymphoma, however the underlying mechanisms are poorly understood. " Order ALL the reference details at left...
4.	Ovarian Neoplasms (Ovarian Cancer) 09/01/2003 - "[Radioimmunotherapy in patients with ovarian cancer in complete remission after the first line surgery and chemotherapy after second look laparoscopy procedure]" 02/01/1996 - "The low-affinity monoclonal antibody (MAb) chimeric 17-1A(c-17-1A) and the high-affinity MAb mouse 323/A3 (m-323/A3) were used to study the effect of the MAb affinity on the tumour uptake and efficacy of radioimmunotherapy in nude mice bearing subcutaneously the human ovarian cancer xenografts FMa, OVCAR-3 and Ov.Pe" 07/01/1997 - "CONCLUSIONS: The favorable physical characteristics of 186Re as well as its efficacy when conjugated to a MAb indicate 186Re as an attractive radionuclide in radioimmunotherapy of ovarian cancer patients." 01/01/2010 - "The aim of this study was to investigate the therapeutic efficacy of alpha-radioimmunotherapy of ovarian cancer in mice using different fractionated treatment regimens. " 08/01/2009 - "PURPOSE: The aim of this study was to investigate the therapeutic efficacy of the alpha-radioimmunotherapy of ovarian cancer in mice, using different specific activities. " Order ALL the reference details at left...
5.	B-Cell Lymphoma (Lymphoma, B Cell) 07/01/1997 - "Radioimmunotherapy, with or without stem-cell transplant support, has produced substantial complete remission rates in chemotherapy-resistant B-cell lymphomas. " 03/01/2006 - "Clinical trials suggest that anti- CD20 radioimmunotherapy is superior to total body irradiation in patients undergoing stem cell supported therapy for B-cell lymphoma, and that it is a safe and efficacious modality when used as consolidation therapy following chemotherapy. " 01/01/2003 - "For more than a decade, radioimmunotherapy has shown great promise for the treatment of B-cell lymphoma. " 10/01/1998 - "PURPOSE: Radioimmunotherapy (RIT) is a promising treatment approach for B-cell lymphomas. " 11/10/2008 - "Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antibodies
2.	Monoclonal Antibodies
3.	Carcinoembryonic Antigen
4.	Antigens
5.	ibritumomab tiuxetan (Zevalin)
6.	Immunoglobulin G (IgG)
7.	Paclitaxel (Taxol)
8.	AB 2
9.	Radioisotopes (Radionuclides)
10.	Immunoconjugates (Immunoconjugate)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Transplants (Transplant)
5.	Injections

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>